| Not Yet Recruiting | Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy NCT07535138 | Air Force Military Medical University, China | EARLY_Phase 1 |
| Not Yet Recruiting | Omics of Rituximab-resistance NCT07416942 | Mario Negri Institute for Pharmacological Research | — |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immu NCT07389499 | Grit Biotechnology | EARLY_Phase 1 |
| Completed | Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy NCT06994468 | Mario Negri Institute for Pharmacological Research | N/A |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combin NCT07038382 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) NCT06341205 | Centre Hospitalier Universitaire de Nice | Phase 3 |
| Not Yet Recruiting | IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients NCT06690359 | Beijing Immunochina Medical Science & Technology Co., Ltd. | EARLY_Phase 1 |
| Recruiting | An Outcome Analysis of Primary Membranous Nephropathy NCT06242327 | Mario Negri Institute for Pharmacological Research | — |
| Not Yet Recruiting | Circulating Factors in Nephrotic Syndrome NCT06315504 | Iain Bressendorff | — |
| Unknown | Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy NCT05941845 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Completed | Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy NCT05894512 | Istanbul University | — |
| Active Not Recruiting | An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases NCT05732402 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephrop NCT05810961 | argenx | Phase 2 |
| Recruiting | Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis NCT05688865 | Chinese University of Hong Kong | — |
| Recruiting | NEPTUNE Match Study NCT04571658 | University of Michigan | N/A |
| Recruiting | Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. NCT05505500 | University of Michigan | — |
| Active Not Recruiting | Obinutuzumab in Primary MN NCT05050214 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy NCT05162066 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | MOR202 for Refractory MN NCT04893096 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Terminated | Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy NCT04652570 | Tenet Medicines | Phase 1 / Phase 2 |
| Completed | A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome NCT04278729 | University of North Carolina, Chapel Hill | Phase 1 |
| Recruiting | Raman Spectroscopy Diagnosis of Kidney Diseases NCT06760845 | Zunsong Wang | — |
| Completed | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) NCT04733040 | HI-Bio, A Biogen Company | Phase 2 |
| Unknown | Immunopathological Analysis in a French National Cohort of Membranous Nephropathy NCT04326218 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | Belimumab With Rituximab for Primary Membranous Nephropathy NCT03949855 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Autoreactive B Cells in Membranous Nephropathy NCT04095156 | Mario Negri Institute for Pharmacological Research | — |
| Recruiting | KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887 | Seoul National University Hospital | — |
| Completed | Adrenocorticotropic Hormone in Membranous Nephropathy NCT03025828 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Completed | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies NCT03453619 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy NCT02199145 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy NCT01955187 | Hospital Universitario 12 de Octubre | Phase 3 |
| Recruiting | Nephrotic Syndrome Study Network NCT01209000 | University of Michigan | — |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropat NCT00518219 | Nanjing University School of Medicine | Phase 4 |
| Completed | Rituximab in the Treatment of Idiopathic Membranous Nephropathy NCT00405340 | Mayo Clinic | EARLY_Phase 1 |
| Completed | The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy NCT00983034 | Istanbul University | N/A |
| Completed | Rituximab in Membranous Nephropathy NCT00425217 | Mayo Clinic | Phase 2 / Phase 3 |